Follow the Science Act

HR7173, titled the "Follow the Science Act," is currently in the initial stages of the legislative process, having been referred to the House Committee on Energy and Commerce on January 21, 2026. This bill seeks to ensure that federal agencies base their decisions on the best available scientific evidence. While the specific details of its implementation are not yet public, its core intent is to standardize and elevate the role of science in government policy. This is a procedural bill that does not allocate specific funding or create new revenue streams for companies. Its impact is on the framework of regulatory decisions rather than direct market activity. There is no direct money trail associated with HR7173. The bill does not appropriate funds for research, grants, or procurement. Therefore, no specific companies are positioned to receive contracts or direct financial benefits from its passage. Its influence would be on the criteria used by agencies like the FDA, EPA, and CDC when making regulatory decisions, potentially affecting the approval processes for products in sectors like pharmaceuticals, biotechnology, and environmental services. However, this is an indirect effect on regulatory certainty rather than a direct financial gain. Historically, legislation focused on scientific integrity or evidence-based policymaking has not generated significant immediate market movements. For example, similar legislative efforts, often embedded in broader appropriations bills or administrative procedure acts, have not caused specific stock surges or declines upon introduction or passage. These types of bills are foundational to governance but do not directly alter market dynamics or corporate earnings. The market typically reacts to direct financial incentives, regulatory changes with clear economic consequences, or shifts in government spending, none of which are present in HR7173. Given the nature of the bill, there are no specific winners or losers among publicly traded companies at this stage. The bill's impact is broad and procedural, affecting the general regulatory environment rather than creating distinct competitive advantages or disadvantages for individual firms. Companies operating in heavily regulated sectors, such as pharmaceuticals ($PFE, $JNJ, $MRK), biotechnology ($AMGN, $GILD, $BIIB), and environmental services ($WM, $RSG), might experience a marginal increase in regulatory predictability if the bill passes and is effectively implemented, but this is not a direct financial catalyst. What happens next is that the bill will undergo review within the House Committee on Energy and Commerce. This process can involve hearings, markups, and potential amendments. If it passes out of committee, it would then proceed to a vote in the full House of Representatives. The timeline for such a procedural bill is often extended, and many bills of this nature do not advance beyond committee. No immediate market-moving events are anticipated in the short term.